-
EP2188307
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2188307
| EP2188307 - GLYCOSAMINOGLYCAN-ANTAGONISING MCP-1 MUTANTS AND METHODS OF USING SAME [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 01.08.2014 Database last updated on 03.09.2024 | Most recent event Tooltip | 01.08.2014 | Application deemed to be withdrawn | published on 03.09.2014 [2014/36] | Applicant(s) | For all designated states ProtAffin Biotechnologie AG Impulszentrum Graz-West Reininghausstrasse 13a 8020 Graz / AT | [N/P] |
| Former [2010/21] | For all designated states Protaffin Biotechnologie AG Impulszentrum Graz-West Reininghausstrasse 13a 8020 Graz / AT | Inventor(s) | 01 /
KUNGL, Andreas Strasserhofweg 77a A-8045 Graz / AT | 02 /
PICCININI, Anna Maria 7 Spencer News Greyhound Road London W6 9PB / GB | 03 /
WEBER, Christian Kaiser-Friedrich-Allee 59 52074 Aachen / DE | [2010/31] |
| Former [2010/21] | 01 /
KUNGL, Andreas Strasserhofweg 77a A-8045 Graz / AT | ||
| 02 /
PICCININI, Anna Maria 803 Fulham Road London SW6 5HE / GB | |||
| 03 /
WEBER, Christian Kaiser-Friedrich-Allee 59 52074 Aachen / DE | Representative(s) | Redl, Gerda REDL Life Science Patent Attorneys Donau-City-Strasse 11 1220 Wien / AT | [N/P] |
| Former [2010/21] | Redl, Gerda REDL Life Science Patent Attorneys Tech Gate Vienna Donau-City-Strasse 1 1220 Vienna / AT | Application number, filing date | 08785241.4 | 31.07.2008 | [2010/21] | WO2008EP06298 | Priority number, date | US20070953140P | 31.07.2007 Original published format: US 953140 P | EP20070450166 | 27.09.2007 Original published format: EP 07450166 | [2010/21] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2009015884 | Date: | 05.02.2009 | Language: | EN | [2009/06] | Type: | A1 Application with search report | No.: | EP2188307 | Date: | 26.05.2010 | Language: | EN | The application published by WIPO in one of the EPO official languages on 05.02.2009 takes the place of the publication of the European patent application. | [2010/21] | Search report(s) | International search report - published on: | EP | 05.02.2009 | Classification | IPC: | C07K14/52 | [2010/21] | CPC: |
C07K14/523 (EP,US);
A61P1/04 (EP);
A61P29/00 (EP);
A61P31/14 (EP);
A61P43/00 (EP);
A61P9/04 (EP);
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR [2010/21] | Extension states | AL | 16.02.2010 | BA | 16.02.2010 | MK | 16.02.2010 | RS | 16.02.2010 | Title | German: | GLYKOSAMINOGLYKANANTAGONISIERENDE MCP-1-MUTANTEN UND VERFAHREN ZU DEREN ANWENDUNG | [2010/21] | English: | GLYCOSAMINOGLYCAN-ANTAGONISING MCP-1 MUTANTS AND METHODS OF USING SAME | [2010/21] | French: | MUTANTS MCP-1 ANTAGONISANT LE GLYCOSAMINOGLYCAN ET LEURS PROCÉDÉS D'UTILISATION | [2010/21] | Entry into regional phase | 16.02.2010 | National basic fee paid | 16.02.2010 | Designation fee(s) paid | 16.02.2010 | Examination fee paid | Examination procedure | 02.06.2009 | Request for preliminary examination filed International Preliminary Examining Authority: EP | 16.02.2010 | Examination requested [2010/21] | 26.07.2010 | Despatch of a communication from the examining division (Time limit: M04) | 20.10.2010 | Reply to a communication from the examining division | 10.02.2012 | Despatch of a communication from the examining division (Time limit: M04) | 19.06.2012 | Reply to a communication from the examining division | 25.10.2013 | Despatch of a communication from the examining division (Time limit: M04) | 05.03.2014 | Application deemed to be withdrawn, date of legal effect [2014/36] | 28.03.2014 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2014/36] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 26.07.2010 | Fees paid | Renewal fee | 27.07.2010 | Renewal fee patent year 03 | 25.07.2011 | Renewal fee patent year 04 | 23.07.2012 | Renewal fee patent year 05 | 22.07.2013 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y]WO2005054285 (KUNGL ANDREAS J [AT]) [Y] 19,20 * page 3 - page 4; claims 2,3,5; table 1 * * page 7 - page 8 * * page 14, paragraph 2 *; | [X]US2003162737 (EGASHIRA KENSUKE [JP], et al) [X] 1-5,10,11,13,15-20 * the whole document *; | [XDY] - JARNAGIN KURT ET AL, "Identification of surface residues of the monocyte chemotactic protein 1 that affect signaling through the receptor CCR2", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, (19991207), vol. 38, no. 49, ISSN 0006-2960, pages 16167 - 16177, XP002336958 [XD] 1-11,13,15-17 * abstract * [Y] 19,20 DOI: http://dx.doi.org/10.1021/bi9912239 | [X] - STEITZ S A ET AL, "Mapping of MCP-1 functional domains by peptide analysis and site-directed mutagenesis", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, (19980703), vol. 430, no. 3, ISSN 0014-5793, pages 158 - 164, XP004258051 [X] 1,5,8,11,13,15,16 * the whole document * DOI: http://dx.doi.org/10.1016/S0014-5793(98)00637-1 | [X] - PAAVOLA CHAD D ET AL, "Monomeric monocyte chemoattractant protein-1 (MCP-1) binds and activates the MCP-1 receptor CCR2B", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, (19981211), vol. 273, no. 50, ISSN 0021-9258, pages 33157 - 33165, XP002283331 [X] 1,4,8,11,13,15,16 * the whole document * DOI: http://dx.doi.org/10.1074/jbc.273.50.33157 | [A] - POTZINGER H ET AL, "Developing chemokine mutants with improved proteoglycan affinity and knocked-out GPCR activity as anti-inflammatory recombinant drugs.", BIOCHEMICAL SOCIETY TRANSACTIONS JUN 2006, (200606), vol. 34, no. Pt 3, ISSN 0300-5127, pages 435 - 437, XP002462147 DOI: http://dx.doi.org/10.1042/BST0340435 | [A] - GESSLBAUER BERND ET AL, "Glycomic approaches toward drug development: therapeutically exploring the glycosaminoglycanome.", CURRENT OPINION IN MOLECULAR THERAPEUTICS DEC 2006, (200612), vol. 8, no. 6, ISSN 1464-8431, pages 521 - 528, XP002462149 | [DA] - LAU ELAINE K ET AL, "Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1 - Implications for structure and function in vivo", JOURNAL OF BIOLOGICAL CHEMISTRY, (20040521), vol. 279, no. 21, ISSN 0021-9258, pages 22294 - 22305, XP002462150 DOI: http://dx.doi.org/10.1074/jbc.M311224200 | [DA] - HEMMERICH STEFAN ET AL, "Identification of residues in the monocyte chemotactic protein-1 that contact the MCP-1 receptor, CCR2", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, (19991005), vol. 38, no. 40, ISSN 0006-2960, pages 13013 - 13025, XP002198634 DOI: http://dx.doi.org/10.1021/bi991029m | [PA] - PROTAFFIN BIOTECHNOLOGIE AG, "CellJammerTM discovery technology", (20070907), URL: http://www.protaffin.com/images/content/pdfs/070907_protaffin_technology_profile.pdf?sid=05laac50gtpn2i073rg8k3mnk6, (20071204), XP002462148 |